Protara Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Protara Therapeutics generated cash of -$37,557,000, which is less than the previous year. Cash used in financing activities reached the amount of -$91,000 last year. Net change in cash is therefore $15,459,000.
Cash Flow
| 2014 | -9.99M | -12.48M | 88.52M |
|---|---|---|---|
| 2015 | -17.56M | -11.33M | 163K |
| 2016 | -23.68M | 19.91M | 208K |
| 2017 | -22.35M | -16.09M | 23.04M |
| 2018 | -23.23M | 18.42M | 2.98M |
| 2019 | -15.64M | 2.48M | 500K |
| 2020 | -23.40M | 2.83M | 189.40M |
| 2021 | -34.50M | -98.19M | -228K |
| 2022 | -26.45M | 14.95M | -90K |
| 2023 | -37.55M | 53.10M | -91K |
TARA Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 24.87M | 36.46M | 169.39M | 564K | 19.39M | 21.19M | 36.39M | 40.03M | 68.84M | 2.79M |
Operating activities | ||||||||||
Net income | -40.42M | -65.95M | -47.25M | -33.97M | -14.99M | -20.72M | -29.96M | -28.52M | -21.37M | -3.34M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 341K | 248K | 117K | 196K | 279K | 115K | 148K | 123K | 57K | 30K |
Stock-based compensation expense | 6.09M | 6.68M | 10.36M | 9.74M | 943K | 0 | 925 | 3.34M | 2.16M | 459K |
| Deferred income tax benefit | 6.09M | 6.68M | 10.36M | 9.74M | 943K | 0 | 925 | 3.34M | 2.16M | 459K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 17K | 0 | -46K | -26K | -32K | 0 |
Inventories | 0 | 0 | 0 | 0 | -17K | 0 | -41.79M | -63.52M | -83.48M | 0 |
Accounts payable | 848K | 631K | 40K | 198K | -2.49M | -6.16M | 4.16M | 1.07M | 1.25M | 955K |
Cash generated by operating activities | -37.55M | -26.45M | -34.50M | -23.40M | -15.64M | -23.23M | -22.35M | -23.68M | -17.56M | -9.99M |
Investing activities | ||||||||||
Purchases Of Investments | -12.18M | -43.55M | -124.74M | 0 | 0 | -15.44M | -32.94M | -39.75M | -88.64M | -34.95M |
Investments In Property Plant And Equipment | -45K | -120K | -596K | -884K | -16K | -119K | -35K | -271K | -198K | -51K |
Acquisitions Net | 0 | -15.07K | 97.59K | 3.71M | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 53.10M | 14.95M | -98.19M | 2.83M | 2.48M | 18.42M | -16.09M | 19.91M | -11.33M | -12.48M |
Financing activities | ||||||||||
Common Stock Issued | 0 | 0 | 0 | 87.85M | 500K | 2.85M | 1.52M | 11K | 163K | 62.48M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | -91K | -90K | -228K | 0 | 0 | 0 | 0 | 208K | 163K | 88.97M |
Repayments of term debt | 0 | 0 | 0 | -1.66M | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | -91K | -90K | -228K | 189.40M | 500K | 2.98M | 23.04M | 208K | 163K | 88.52M |
Net Change In Cash | 15.45M | -11.59M | -132.92M | 168.82M | -13.16M | -1.79M | -15.22M | -3.63M | -28.80M | 66.04M |
Cash at end of period | 40.33M | 24.87M | 36.46M | 169.39M | 6.23M | 19.39M | 21.17M | 36.39M | 40.03M | 68.83M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |